This review provides a succinct discussion of the biology of incretins, proposed mechanisms of action of GLP-1 receptor agonists, clinical evidence to date demonstrating kidney benefits with GLP-1 and dual GLP-1/GIP receptor agonists, and overview of current recommendations for GLP-1 receptor agonist use in patients with T2D and DKD. The gene discussed is GLP1R; the disease is diabetic kidney disease.